Chimeric Therapeutics Limited · ASX:CHM
Chimeric Therapeutics — Shareholder Meeting (November 2025)
7 slides from Chimeric Therapeutics's shareholder meeting presentation, Nov 25, 2025
Slide 1: Pioneers in Cell Therapy
For personal use only CHI MERIC THE RAP EU TICS 25 20 PIONEERS IN CELL THERAPY CHIMERIC ASX: CHM
Slide 2: Disclaimer
DISCLAIMER Certain statements contained in this presentation, including, without contained herein to reflect future events or developments except as limitation, statements containing the words “believes,” “plans,” required by law. “expects,” “anticipates,” and words of similar import, constitute Thi
Slide 3: CHM: Broad Portfolio
3 CHM: BROAD PORTFOLIO 3 Novel cell therapies; 4 Clinical Trials For personal use only CHM CDH17 CHM CORE-NK CHM CLTX CAR-T ‘OFF THE SHELF’ NK CHI MERIC THE RAP EU TICS PHASE 1B PHASE 1B TRIAL OPEN TRIAL OPEN PHASE 1/2 TRIAL OPEN PHASE 1B TRIAL 4 sites active MD Anderson Case Western 1 site active 2
Slide 4: CHM CDH17 Progress as at Nov 24th, 2025
4 CHM CDH17 PROGRESS AS AT NOV 24TH, 2025 FIVE ONGOING STABLE DISEASE Dose Level Status Notes For personal use only 1 50m Completed 4 pts treated 1 pt remains on study 12months ongoing Stable Disease CHI MERIC THE RAP EU TICS 2 150m Recruitment Ongoing 5 patients treated 4 pts achieved ongoing Stabl
Slide 5: CHM CORE-NK Frontline Phase Study Results
CHM CORE-NK FRONTLINE PHASE 1 STUDY RESULTS 5 Four Completes Responses, 1 Partial Response For personal use only Dose escalation Relapse Refractory Patients completed 1 Complete Response CHI MERIC THE RAP EU TICS First line FrontLine Patients with no prior treatment Dosing 3 Complete Responses Under
Slide 6: Summary
SUMMARY 9 patients treated For personal use only 10/10 manufacturing runs CHM CDH17 Tumour shrinkage observed 10 CHM 2101 Manageable safety profile CHI MERIC THE RAP EU TICS No off-target effects Investigator Sponsored Trial at MD ANDERSON Dose Escalation completed CHM CORE-NK First Line Dosing Unde
Slide 7: Chimeric: Pioneers in Cell Therapy
For personal use only CHIMERIC CHI MERIC THE RAP EU TICS PIONEERS IN CELL THERAPY investors@chimerictherapeutics.Com ASX: CHM 20 25
Chimeric Therapeutics — Shareholder Meeting (November 2025) on 6ix